Sign in
4

Changes in Ownership

Dyne Therapeutics, Inc. Filed Acc 0001193125-26-096523

Chief Commercial Officer sold 148 shares at $14.90 ($2,205)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Friedl-Naderer Johanna · Chief Commercial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2026-03-05 Sale : show line 1 in the form 10b5-1 −148 $14.90 $2,205 154,581 D
Open-market sales · 148 sh · avg $14.90 · $2,205
Loading xslF345X05/ownership.xml…